KOD Kodiak Sciences Inc. stock chart & analysis
Conviction 0HealthcareScan · Fri, Nov 6, 2026Kodiak Sciences Inc. (KOD) closed at $99.30 (+9.10%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 62, RS Rating 99, -4.5% from its 52-week high, +255.2% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Why KOD moved
From the StockSetups movers recaps that covered KOD, newest first. A recap states what was known that day.
- Close+178.2%
This was a clear, confirmed catalyst. Kodiak Sciences presented topline results from its DAYBREAK Pivotal Phase 3 study — a trial evaluating Zenkuda and KSI-501 in patients with wet age-related macular degeneration (AMD), a leading cause of vision loss.
Top Stock Movers Sept 28, 2026: KOD, KNRX, CLRO → - Premarket+96.4%
Kodiak Sciences released topline results from the DAYBREAK pivotal Phase 3 study of its wet age-related macular degeneration (wet AMD) treatments — Zenkuda and KSI-501 — this morning.
Premarket Movers Sept 28, 2026: KOD, GYGY, CLRO →
Financials as of Tue, Jun 30, 2026 · quarterly.
KOD technical analysis
Trend
KOD is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 42.8% above the 50-day ($69.56) and 126.5% above the 200-day ($43.84). ADX(14) at 35 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 62, in the bullish half of its range. The MACD histogram is negative. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $94.6M a day on average. ATR(14) is $6.68, 6.7% of price — its typical daily range. Chaikin Money Flow (-0.18) shows distribution.
Key levels
The chart pattern's support is $30.68 and its resistance $103.67. The 52-week range is $15.83 to $104.00; price is 4.5% below the high and 527.2% above the low. The VWAP anchored at the 52-week high is $93.40, below price.
Performance
KOD returned +0.1% (1 week), +5.4% (1 month), +128.8% (3 months), +142.2% (6 months), +457.0% (1 year), +255.2% (year to date).
About Kodiak Sciences Inc.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Biological Products, (No Diagnostic Substances) · Listed 2018 · 124 employees
Insider activity
SEC Form 4 transactions in KOD · open-market 4 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP Director · Common Stock · 2026-11-05 | Buy | 4.7K | $463K | 2026-11-05 | 2026-11-06 |
BAKER BROS. ADVISORS LP Director · Common Stock · 2026-11-05 | Buy | 81.73K | $8.1M | 2026-11-05 | 2026-11-06 |
BAKER BROS. ADVISORS LP Director · Common Stock · 2026-11-04 | Buy | 151.92K | $15M | 2026-11-04 | 2026-11-06 |
BAKER BROS. ADVISORS LP Director · Common Stock · 2026-11-04 | Buy | 8.74K | $861K | 2026-11-04 | 2026-11-06 |
Yang Taiyin Director · Common Stock · 2026-10-23 | Exercise | 20K | $47K | 2026-10-23 | 2026-10-26 |
Yang Taiyin Director · Stock Option (Right to Buy) · 2026-10-23 | Exercise | 20K | — | 2026-10-23 | 2026-10-26 |
PERLROTH VICTOR Chairman and CEO · Stock Option (Right to Buy) · 2026-07-15 | Grant | 100K | — | 2026-07-15 | 2026-07-17 |
BORGESON JOHN A. Chief Financial Officer · Stock Option (Right to Buy) · 2026-07-15 | Grant | 66.5K | — | 2026-07-15 | 2026-07-17 |
BORGESON JOHN A. Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-04 | Exercise | 30K | $0 | 2026-06-04 | 2026-06-05 |
BORGESON JOHN A. Chief Financial Officer · Common Stock · 2026-06-04 | Sell | 25.9K | $881K | 2026-06-04 | 2026-06-05 |
SEC filings
EDGAR filings in KOD · 9 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.